HIV-related CD8+ cutaneous pseudolymphoma: efficacy of methotrexate.
Human immunodeficiency virus (HIV)-related CD8+ cutaneous pseudolymphoma (CD8+ cytotoxic T cell skin infiltrative disease) is an inflammatory process resulting from a massive infiltration of the skin by activated, oligoclonal, HIV-specific, cytotoxic T lymphocytes. Usually, CD8+ cutaneous pseudolymphoma affects patients with a deep immunosuppression, and is rare in patients with mild immunosuppression. In deeply immunocompromised patients, highly active antiretroviral therapy (HAART) is considered as the first-line treatment. In contrast, the choice of therapy in moderately immunocompromised patients and/or patients already receiving HAART remains nonconsensual. We report a case of HIV-related CD8+ cutaneous pseudolymphoma in a moderately immunocompromised patient who was successfully and safely treated with methotrexate. We review the literature on HIV-related CD8+ pseudolymphoma and the use of methotrexate in HIV-positive patients.
Department of Dermatology, AP-HP, Henri Mondor Hospital, FR-94000 Créteil, France. saskia.oro@hmn.aphp.fr
S
S
Ingen-Housz-Oro
E
E
Sbidian
N
N
Ortonne
D
D
Penso-Assathiany
V
V
Chambrin
M
M
Bagot
H
H
Bachelez
P
P
Wolkenstein
O
O
Chosidow
D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D019310:Pseudolymphoma / Q000188:drug therapy* / Q000276:immunology; D012871:Skin Diseases / Q000188:drug therapy* / Q000276:immunology; D016896:Treatment Outcome
D003879:Dermatologic Agents; D008727:Methotrexate